相似文献
1
Dual roles of TLR7 in the lung cancer microenvironment.
Oncoimmunology. 2015 Jan 9;4(3):e991615. doi: 10.4161/2162402X.2014.991615. eCollection 2015 Mar.
2
Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.
Mol Cancer Ther. 2010 Jun;9(6):1788-97. doi: 10.1158/1535-7163.MCT-09-1198. Epub 2010 Jun 1.
3
Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells.
Oncoimmunology. 2018 Oct 11;8(1):e1505174. doi: 10.1080/2162402X.2018.1505174. eCollection 2019.
4
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
J Immunother Cancer. 2019 Sep 11;7(1):244. doi: 10.1186/s40425-019-0724-8.
5
Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.
J Clin Invest. 2010 Apr;120(4):1285-97. doi: 10.1172/JCI36551. Epub 2010 Mar 8.
6
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
Oncologist. 2008 Aug;13(8):859-75. doi: 10.1634/theoncologist.2008-0097. Epub 2008 Aug 13.
7
Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
J Cancer Res Clin Oncol. 2017 Sep;143(9):1713-1732. doi: 10.1007/s00432-017-2421-7. Epub 2017 Apr 21.
8
TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer.
Cancer Res. 2014 Sep 15;74(18):5008-18. doi: 10.1158/0008-5472.CAN-13-2698. Epub 2014 Jul 29.
9
Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
J Immunotoxicol. 2009 Dec;6(4):257-65. doi: 10.3109/15476910903286733.
10
Exosomal FMR1-AS1 facilitates maintaining cancer stem-like cell dynamic equilibrium via TLR7/NFκB/c-Myc signaling in female esophageal carcinoma.
Mol Cancer. 2019 Feb 8;18(1):22. doi: 10.1186/s12943-019-0949-7.
引用本文的文献
1
Retroelement co-option disrupts the cancer transcriptional programme.
Genome Med. 2025 May 7;17(1):48. doi: 10.1186/s13073-025-01479-9.
2
Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy.
Biomaterials. 2025 Jan;312:122750. doi: 10.1016/j.biomaterials.2024.122750. Epub 2024 Aug 8.
3
Toll-like Receptors: Key Players in Squamous Cell Carcinoma Progression.
J Clin Med. 2024 Aug 2;13(15):4531. doi: 10.3390/jcm13154531.
4
Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system.
Front Immunol. 2023 Nov 23;14:1294434. doi: 10.3389/fimmu.2023.1294434. eCollection 2023.
5
Cuproptosis and Immune-Related Gene Signature Predicts Immunotherapy Response and Prognosis in Lung Adenocarcinoma.
Life (Basel). 2023 Jul 19;13(7):1583. doi: 10.3390/life13071583.
6
The future of cancer immunotherapy: DNA vaccines leading the way.
Med Oncol. 2023 Jun 9;40(7):200. doi: 10.1007/s12032-023-02060-3.
7
A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer.
Front Oncol. 2023 Jan 30;13:1095313. doi: 10.3389/fonc.2023.1095313. eCollection 2023.
8
Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer.
Cancers (Basel). 2023 Jan 16;15(2):543. doi: 10.3390/cancers15020543.
9
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives.
Biomark Res. 2022 Dec 7;10(1):89. doi: 10.1186/s40364-022-00436-7.
10
Understanding the role of Toll-like receptors in lung cancer immunity and immunotherapy.
Front Immunol. 2022 Oct 31;13:1033483. doi: 10.3389/fimmu.2022.1033483. eCollection 2022.
本文引用的文献
1
TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer.
Cancer Res. 2014 Sep 15;74(18):5008-18. doi: 10.1158/0008-5472.CAN-13-2698. Epub 2014 Jul 29.
2
Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma.
Liver Int. 2015 Mar;35(3):1063-76. doi: 10.1111/liv.12626. Epub 2014 Jul 30.
3
Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment.
Cancer Res. 2013 Aug 1;73(15):4629-40. doi: 10.1158/0008-5472.CAN-12-3058. Epub 2013 May 30.
4
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans.
J Clin Invest. 2012 Nov;122(11):4118-29. doi: 10.1172/JCI63606.
5
Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
Int J Cancer. 2013 Feb 1;132(3):580-90. doi: 10.1002/ijc.27691. Epub 2012 Jul 11.
6
A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes.
J Am Acad Dermatol. 2012 Apr;66(4):e131-7. doi: 10.1016/j.jaad.2011.11.933. Epub 2012 Jan 9.
7
Immunomodulation by imiquimod in patients with high-risk primary melanoma.
J Invest Dermatol. 2012 Jan;132(1):163-9. doi: 10.1038/jid.2011.247. Epub 2011 Aug 18.
8
Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.
Mol Cancer Ther. 2010 Jun;9(6):1788-97. doi: 10.1158/1535-7163.MCT-09-1198. Epub 2010 Jun 1.
9
Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.
J Clin Invest. 2010 Apr;120(4):1285-97. doi: 10.1172/JCI36551. Epub 2010 Mar 8.
10
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.
Cancer Res. 2006 Apr 1;66(7):3859-68. doi: 10.1158/0008-5472.CAN-05-3948.
Zotero 插件